PharmaFrontiers

PharmaFrontiers was a biotechnology company primarily focused on the development of autologous cell therapies for autoimmune diseases and regenerative medicine. The company's lead candidate, Tovaxin, was an individualized T-cell immunotherapy designed to treat multiple sclerosis by targeting specific myelin-reactive T-cells. In addition to its immunotherapy pipeline, the company held intellectual property related to the use of adult stem cells for various regenerative applications. In 2006, PharmaFrontiers underwent a significant corporate rebranding and changed its name to Opexa Therapeutics to better reflect its focus on personalized cellular medicine.